← Leaderboards
Rachel A Woolaver
University Of Colorado Denver
$100,344
Attributed
$100,344
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $34.1K · FY2018–20$50K$37.5K$25K$12.5K$0
'18
'19
'20
Funding mix
By agency
NIH$100,344 · 1
By mechanism
F31$100,344 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Antonio Jimeno$15,496,689
- Andrew S Kraft$21,224,247
- Scott A Weed$3,997,953
- Sana D Karam$9,495,305
- Shi-Long Lu$3,811,941
Others in their field
Other Emerging Leaders on “Affect”
- Chanza Baytop · Westat, Inc.$271,217,917
- Leonard Freedman · Leidos Biomedical Research, Inc.$62,378,387
- Jennifer Marie Suga · Kaiser Foundation Research Institute$29,218,159
- Lynn Briscoe · Leidos Biomedical Research, Inc.$27,788,199
- George Robert Painter · University Of Alabama At Birmingham$27,619,145
- Jessica Brooke Langbaum · Banner Health$22,633,312
Research focus
AffectAutomobile DrivingBiological MarkersAntitumor ResponseCancer ImmunotherapyCd8b1 GeneCellsCessation Of LifeCharacteristicsComplexDesignEfficacy TestingEnvironmentEquilibriumExhaustExhaustionExhibitsExperimental StudyFailureFoundationsGene ActivationGrowthHead And Neck CancerHead And Neck Squamous Cell Carcinoma
Grant awards (3)
Mechanisms underlying therapy failure of immune checkpoint inhibitors and Notch1 loss-mediated immunosuppression in head and neck cancers$32,919
F31 · FY2020 · DE · contact PI
Mechanisms underlying therapy failure of immune checkpoint inhibitors and Notch1 loss-mediated immunosuppression in head and neck cancers$34,137
F31 · FY2019 · DE · contact PI
Mechanisms underlying therapy failure of immune checkpoint inhibitors and Notch1 loss-mediated immunosuppression in head and neck cancers$33,288
F31 · FY2018 · DE · contact PI